The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation

Samankaltaisia teoksia

• Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
  Tekijä: Morris E Feldman, et al.
  Julkaistu: (2009-02-01)
• Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
  Tekijä: Euphemia Y Leung, et al.
  Julkaistu: (2015-01-01)
• Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
  Tekijä: Quan Wang, et al.
  Julkaistu: (2013-01-01)
• Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
  Tekijä: Liu, Qingsong, et al.
  Julkaistu: (2015)
• Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1
  Tekijä: Qin Xia, et al.
  Julkaistu: (2021-12-01)